Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 15/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3920773 | 0.94 | NR1H2 (0.44) | NR1H2NR1H3SRD5A2TRPV3MEN1 | |
| Tert-Butanol SCHEMBL3930132 | 0.91 | NR1H2 (0.43) | NR1H2NR1H3SRD5A2TRPV3MAOB | |
| Tert-Butanol SCHEMBL3922292 | 0.90 | NR1H2 (0.39) | NR1H2NR1H3SRD5A2TRPV3MEN1 | |
| SCHEMBL3918504 | 0.88 | NR1H2 (0.44) | NR1H2NR1H3SRD5A2TRPV3 | |
| SCHEMBL3931449 | 0.87 | NR1H2 (0.52) | NR1H2NR1H3 | |
| SCHEMBL3973776 | 0.86 | NR1H2 (0.42) | NR1H2NR1H3SRD5A2MAOBMEN1 | |
| SCHEMBL3921577 | 0.85 | NR1H2 (0.45) | NR1H2NR1H3SRD5A2TRPV3MEN1 | |
| SCHEMBL3920962 | 0.85 | NR1H2 (0.45) | NR1H2NR1H3SRD5A2TRPV3MEN1 | |
| SCHEMBL3920246 | 0.84 | NR1H2 (0.41) | NR1H2NR1H3SRD5A2TRPV3MEN1 | |
| SCHEMBL3921277 | 0.84 | NR1H2 (0.41) | NR1H2NR1H3SRD5A2TRPV3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491710-B2 | Organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2009-02-17 | — | — | US | disclosed |
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | AVENTIS PHARMA S.A. (FR) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137171-A1 | Novel organophosphorus derivatives of indazoles and use thereof as medicinal products | PPIP5K2, INPPL1, IP6K3 | NR1H2 2030/4885NR1H3 1492/4885SRD5A2 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.